2020
The evanescence and persistence of RBC alloantibodies in blood donors
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena‐Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE, Tormey CA, ). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion 2020, 60: 831-839. PMID: 32061102, DOI: 10.1111/trf.15718.Peer-Reviewed Original ResearchConceptsBlood donorsAntibody persistenceAntibody screenDonor Evaluation Study-IIIHistory of transfusionUS blood centersFit inclusion criteriaPresence of alloantibodiesRecipient EpidemiologyRBC alloantibodiesBlood productsInclusion criteriaSignificant antibodiesBiologic factorsHealthy populationAntibody detectionAntibody identificationAlloantibodiesBlood centersMultiple antibodiesFirst donationAntibody specificityStudy IIIAntibodiesCenter policies
2017
Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys
Julg B, Sok D, Schmidt S, Abbink P, Newman R, Broge T, Linde C, Nkolola J, Le K, Su D, Torabi J, Pack M, Pegu A, Allen T, Mascola J, Burton D, Barouch D. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Journal Of Virology 2017, 91: 10.1128/jvi.01187-17. PMID: 28768869, PMCID: PMC5625479, DOI: 10.1128/jvi.01187-17.Peer-Reviewed Original ResearchConceptsImmunodeficiency virusProtective effects <i>inNeutralizing antibodiesSimian-human immunodeficiency virusCirculating HIV strainsResistant to antibody neutralizationRhesus macaquesBroadly Neutralizing AntibodiesPlasma viremiaIncreased levelsSterile protectionHIV strainsBnAbsPGT121Neutralizing activityAntibody neutralizationVirus-antibody combinationsIncomplete neutralizationControl animalsMultiple antibodiesRhesus monkeysPrevent infectionProtective efficacySterilizing activityInput virus
2015
Concomitant opsoclonus ataxia and limbic encephalitis as a result of dual anti‐Ri and anti‐Yo antibodies in uterine carcinosarcoma: A case report
Kim J, Pinto A, Nucci M, Lyons J. Concomitant opsoclonus ataxia and limbic encephalitis as a result of dual anti‐Ri and anti‐Yo antibodies in uterine carcinosarcoma: A case report. Clinical And Experimental Neuroimmunology 2015, 7: 75-78. DOI: 10.1111/cen3.12249.Peer-Reviewed Original ResearchAnti-Yo antibodiesLimbic encephalitisParaneoplastic syndromeUterine carcinosarcomaParaneoplastic antibodiesPresence of malignancyAnti-RiConcomitant syndromeOpsoclonus-MyoclonusNeurological symptomsCase reportDegeneration syndromeCase presentationSyndromeTumor sourceEncephalitisMultiple antibodiesCarcinosarcomaAntibodiesAtaxiaMyoclonusMalignancySymptomsCases
2012
39-P INCREASING MFI CUTOFFS FOR UNACCEPTABLE ANTIGENS INCREASES ACCESS TO ACTUAL DECEASED DONOR CROSSMATCHES FOR THE SENSITIZED RECIPIENT
Miller M, Alberghini T, Rewinski M, Bow L. 39-P INCREASING MFI CUTOFFS FOR UNACCEPTABLE ANTIGENS INCREASES ACCESS TO ACTUAL DECEASED DONOR CROSSMATCHES FOR THE SENSITIZED RECIPIENT. Human Immunology 2012, 73: 74. DOI: 10.1016/j.humimm.2012.07.165.Peer-Reviewed Original ResearchUnacceptable antigensB cellsB-cell crossmatchPositive flow crossmatchLow-level antibodyHLA class IResultsFifty-sixSensitized recipientsKidney transplantationPositive crossmatchFlow crossmatchVirtual crossmatchDonor workupDP antibodiesNegative control seraLuminex assaysCrossmatchHigh MFI valuesControl seraFlow cytometryMultiple antibodiesClass IRecipientsAntibodiesMatch runsCytoplasmic Estrogen Receptor in Breast Cancer
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Cytoplasmic Estrogen Receptor in Breast Cancer. Clinical Cancer Research 2012, 18: 118-126. PMID: 21980134, PMCID: PMC3263348, DOI: 10.1158/1078-0432.ccr-11-1236.Peer-Reviewed Original ResearchConceptsEstrogen receptorCytoplasmic stainingCytoplasmic ERCytoplasmic estrogen receptorSpecific cytoplasmic stainingCell line seriesHuman breast tumorsQuantitative immunofluorescent analysisRoutine clinical valueRetrospective cohortTamoxifen resistanceBreast cancerLower incidencePreclinical modelsClinical valueTissue microarrayPatient controlsBreast tumorsNumber of casesClinical specimensMultiple antibodiesWestern blotAverage incidenceAntibodiesCohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply